IP Library Granted Patent US 9,592,278
Granted Patent B2
US 9,592,278 · App. 13/777,153 · Granted Mar 14, 2017

Enzyme-activated collagen and tissue matrices

Inventors: Wenquan Sun (Warrington, PA); Xiaohua Yu (Willimantic, CT)
Assignee: LifeCell Corporation
A61K38/4886A61L27/362A61L27/3604A61L27/3687A61L2300/254
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,592,278
App. No.
13/777,153
Granted
Mar 14, 2017
Kind
B2
Abstract

Devices and methods for treating defects in connective tissue are provided along with methods for making such devices. The devices can include enzyme-activated acellular tissue matrices that facilitate regrowth of the damaged tissue.

Claims (21)

1. A tissue matrix composition comprising:

a collagen-based acellular tissue matrix;

at least one protease, wherein the protease consists essentially of at least one of MMP-1, MMP-3, or MMP-9 and can cleave one or more matrikines from the tissue matrix; and

a deactivating agent comprising one or more chelators for reducing the activity of the at least one protease by binding metal ions needed for activity of the at least one protease.

2. The tissue matrix composition of claim 1 , wherein the acellular tissue matrix comprises an acellular dermal matrix.

3. The tissue matrix composition of claim 1 , wherein the acellular tissue matrix comprises an acellular porcine dermal matrix.

4. The tissue matrix composition of claim 1 , wherein the at least one protease is in a solution.

5. The tissue matrix composition of claim 1 , further comprising at least one of an elastase or a dipase.

6. The tissue matrix composition of claim 1 , wherein the chelating agent comprises EDTA, EGTA, or orthophenanthroline.

7. The tissue matrix composition of claim 6 , wherein the chelator is present in a solution at a concentration between 4 mM and 20 mM.

8. The tissue matrix composition of claim 1 , wherein the tissue matrix has been exposed to a disinfectant.

9. The tissue matrix composition of claim 8 , wherein the disinfectant is isopropyl alcohol.

10. The tissue matrix composition of claim 1 , wherein the tissue matrix has been sterilized.

11. The tissue matrix composition of claim 10 , wherein sterilizing the matrix comprises application of ethylene oxide, propylene, gamma irradiation, or e-beam irradiation.

12. The tissue matrix composition of claim 1 , wherein the tissue matrix has been freeze-dried.

13. The tissue matrix composition of claim 1 , wherein the tissue matrix can be stored in hydrated state.

14. The tissue matrix of claim 1 , further comprising a bioactive substance.

15. The tissue matrix composition of claim 14 , wherein the bioactive substance comprises an antibacterial agent, a cytokine, a growth factor, non-collagenous tissue, or cells.

16. The tissue matrix composition of claim 1 , wherein activity of the protease can be restored upon implantation into a subject.

17. The tissue matrix composition of claim 1 , wherein the matrikines comprise GHK (SEQ ID NO: 1), CNYYSNS (SEQ ID NO: 2), VGPVG (SEQ ID NO: 3), VGVAPG (SEQ ID NO: 4), KKGHK (SEQ ID NO: 5), or DGGRYY (SEQ ID NO: 6).

18. The tissue matrix composition of claim 1 , wherein the chelator is present in a solution at a concentration between 4 mM and 20 mM.

Assignments (7)
RELEASE OF SECURITY INTEREST 037845/0497 Recorded Feb 2, 2017
From: WILMINGTON TRUST
To: LIFECELL CORPORATION
Reel/Frame 041608/0603 →
RELEASE OF SECURITY INTEREST 040098/0268 Recorded Feb 2, 2017
From: WILMINGTON TRUST
To: LIFECELL CORPORATION
Reel/Frame 041608/0554 →
RELEASE OF SECURITY INTEREST 040291/0237 Recorded Feb 2, 2017
From: WILMINGTON TRUST
To: LIFECELL CORPORATION
Reel/Frame 041608/0702 →
LIMITED THIRD LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Oct 7, 2016
From: KCI USA, INC.; LIFECELL CORPORATION; KCI LICENSING, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 040291/0237 →
SECOND LIEN SECURITY AGREEMENT Recorded Sep 21, 2016
From: KCI USA, INC.; LIFECELL CORPORATION; KCI LICENSING, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 040098/0268 →
SECURITY INTEREST Recorded Feb 17, 2016
From: KINETIC CONCEPTS, INC.; KCI USA, INC.; ACELITY L.P. INC.; CHIRON HOLDINGS, INC.; CHIRON TOPCO, INC.; KCI ANIMAL HEALTH, LLC; KCI HOLDING COMPANY, INC.; KCI HOMECARE, INC.; KCI IMPORTS, INC.; KCI INTERNATIONAL, INC.; KCI LICENSING, INC.; KCI PROPERTIES LIMITED; KCI REAL HOLDINGS, L.L.C.; KCI REAL PROPERTY LIMITED; KCI USA REAL HOLDINGS, L.L.C.; LIFECELL CORPORATION; TECHNIMOTION, LLC
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 037845/0497 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 26, 2013
From: SUN, WENQUAN; YU, XIAOHUA
To: LIFECELL CORPORATION
Reel/Frame 029876/0800 →
Continuity (2)
Provisional Application 61608458 · Mar 8, 2012
Related Publication 20130236439A1 · Sep 12, 2013